TEGLeg: Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs
Study Details
Study Description
Brief Summary
This study aims to assess possible alteration in coagulation (blood clotting) following treatment with sequential compression devices (SCD) plus low-molecular weight heparin (LMWH) as opposed to LMWH alone.
The investigators will examine coagulation in the early postoperative period of patients undergoing major abdominal surgery during their stay in our Intensive Care Unit.
In addition to common laboratory tests, the investigators will examine coagulation using TEG®, a device which allows a semi-quantitative examination of all phases of coagulation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Low molecular weight heparins (LMWH) are routinely used in perioperative prophylaxis of thromboembolic complications [(chiefly deep vein thrombosis (DVT)]. LMWHs have been proved to be safe and equipotent or superior when compared with unfractionated heparin.
Sequential compressing devices (SCD) are relatively novel pneumatic stockings with several air chambers. A computerized pump applies a gradient of pressure which decreases from the foot cranially. Pressure is also applied intermittently according to predetermined schedules. This devices are being employed for DVT prophylaxis in patients for whom anticoagulation therapy is contraindicated, or in those who have a low risk of DVT. They have also been employed to complement anticoagulant therapy in patients at high risk of DVT, such as those undergoing orthopedic surgery (Fordyce, 1992; Handoll, 2002; Warwick, 2002; Pitto, 2004).
The mechanism of action of SCD seems to be primarily mechanical, through a displacement of a column of blood through the venous system and towards the heart; they act as a surrogate of the muscular pump in immobilized patients (Killewich, 1995).
There is also some evidence that SCD activity may influence the coagulation/fibrinolysis system towards hypocoagulability (Dai, 2000; Kohro, 2003); Kohro and colleagues have also hypothesized that the shear forces generated by SCD may alter platelet adhesion by a direct effect on platelets and/or by increasing the release of factors from the venous endothelium (Kohro, 2005).
The investigators aim to assess the effects on coagulation when SCD are applied to patients at high risk of DVT in addition to standard LMWH therapy.The investigators chose to study a population in whom SCD may be useful in reducing the incidence of DVT, such as patients undergoing postoperative monitoring in the intensive care unit (ICU) after major abdominal surgery for cancer.
In addition to standard laboratory tests, the investigators will use thrombelastography (TEG®) to assess all phases of coagulation. A TEG parameter, maximum amplitude (MA), has been linked to an increase of thrombotic complications in a postoperative population (McCrath, 2005).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SCD + LMWH This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery. |
Device: Sequential compression device therapy
Pneumatic stockings will be applied to patients.
Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery.
Other Names:
Drug: Dalteparin
2500 UI qd if ≤ 50 kg body weight
5000 UI qd if > 50 kg
Other Names:
Procedure: TEG
A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.
TEG analyses will be run at:
Patient admission (before SCD start)
40-60 min after admission
Morning after surgery
Other Names:
|
| Active Comparator: LMWH only Patients in this group will receive only standard LMWH therapy during their ICU stay. |
Drug: Dalteparin
2500 UI qd if ≤ 50 kg body weight
5000 UI qd if > 50 kg
Other Names:
Procedure: TEG
A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.
TEG analyses will be run at:
Patient admission (before SCD start)
40-60 min after admission
Morning after surgery
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Reduction in the area under the curve of maximum amplitude (MA) TEG value over time [24 hours from application of SCD]
Secondary Outcome Measures
- Reduction in the area under the curve of the r time TEG value over time [24 h after application of SCD]
- Reduction in the area under the curve of the alpha angle TEG value over time [24 h after application of SCD]
- Incidence of hypotension (mean arterial pressure ≤60 mmHg) [≤24 h after application of SCD]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Elective major abdominal surgery for neoplasm
-
Planned admission to postsurgical ICU due to the patient's meeting one or more of the following:
-
ASA Physical Status Class 4
-
Surgery of modified Johns-Hopkins class ≥IV
-
ASA 3 with modified Johns-Hopkins class 3 surgery
-
Expected duration of surgery ≥8 h
Exclusion Criteria:
-
History of coagulation abnormalities, either congenital or acquired
-
Ongoing treatment with anticoagulants/antiplatelet agents other than LMWH or hormones
-
Massive edema of the legs
-
Severe peripheral arteriopathy or neuropathy
-
Malformations or recent surgery/trauma to the lower extremities
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital / Azienda Ospedaliero-Universitaria | Parma | PR | Italy | 43100 |
Sponsors and Collaborators
- University of Parma
Investigators
- Study Chair: Guido Fanelli, MD, University of Parma
- Principal Investigator: Maria Barbagallo, MD, UO II Anestesia e Rianimazione, Azienda Ospedaliero-Universitaria di Parma
Study Documents (Full-Text)
None provided.More Information
Publications
- Dai G, Tsukurov O, Orkin RW, Abbott WM, Kamm RD, Gertler JP. An in vitro cell culture system to study the influence of external pneumatic compression on endothelial function. J Vasc Surg. 2000 Nov;32(5):977-87.
- Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg Br. 1992 Jan;74(1):45-9.
- Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev. 2002;(4):CD000305. Review.
- Killewich LA, Sandager GP, Nguyen AH, Lilly MP, Flinn WR. Venous hemodynamics during impulse foot pumping. J Vasc Surg. 1995 Nov;22(5):598-605. Erratum in: J Vasc Surg 1996 Feb;23(2):240.
- Kohro S, Yamakage M, Sato K, Sato JI, Namiki A. Intermittent pneumatic foot compression can activate blood fibrinolysis without changes in blood coagulability and platelet activation. Acta Anaesthesiol Scand. 2005 May;49(5):660-4.
- Kohro S, Yamakage M, Takahashi T, Ota K, Kondo M, Namiki A. Effects of intermittent pneumatic foot compression on blood coagulability and fibrinolysis assessed by a whole blood viscometer Sonoclot. J Anesth. 2003;17(3):208-10.
- McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005 Jun;100(6):1576-1583. doi: 10.1213/01.ANE.0000155290.86795.12.
- Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br. 2004 Jul;86(5):639-42.
- Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002 Apr;84(3):344-50.
- ICU-ICU-01